FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology, medicine and bioinformatics, in particular to a method for selecting neoepitopes for an individual by selecting MHC I and/or MHC II binding neoepitopes and ranking them in terms of their clinical applicability. Present invention also relates to anticancer vaccines obtained by a method involving a step for selecting neoepitopes.
EFFECT: invention enables to obtain vaccines suitable for personalized anticancer therapy.
19 cl, 10 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTING CANCER MUTATIONS TO CREATE PERSONALIZED CANCER VACCINE | 2019 |
|
RU2809620C2 |
| PREDICTION OF IMMUNOGENICITY OF T-CELL EPITOPES | 2014 |
|
RU2724370C2 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| INDIVIDUALISED VACCINES FOR CANCER | 2012 |
|
RU2670745C9 |
| CANCER TUMOUR RESPONSE DETERMINANTS FOR IMMUNOTHERAPY | 2014 |
|
RU2707530C2 |
| METHOD OF PRODUCING A PHARMACEUTICAL AGENT FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2719033C2 |
| METHODS FOR PREDICTION OF APPLICABILITY OF PROTEINS OR PROTEIN FRAGMENTS FOR IMMUNOTHERAPY | 2017 |
|
RU2782336C2 |
| INDIVIDUALIZED ANTI-TUMOR VACCINES | 2012 |
|
RU2779946C2 |
| METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CD4+ T-CELL CHARACTERIZATION | 2019 |
|
RU2826261C2 |
| MODIFIED EPITOPES FOR AMPLIFYING RESPONSES OF CD4+ T-CELLS | 2013 |
|
RU2724994C2 |
